BML-210
CAS No. 537034-17-6
BML-210( BML210 | BML 210 )
Catalog No. M14907 CAS No. 537034-17-6
A novel histone deacetylase (HDAC) inhibitor that induces Ac-histone in A549 cells with EC50 of 181 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 31 | In Stock |
|
| 5MG | 48 | In Stock |
|
| 10MG | 69 | In Stock |
|
| 25MG | 115 | In Stock |
|
| 50MG | 186 | In Stock |
|
| 100MG | 332 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBML-210
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel histone deacetylase (HDAC) inhibitor that induces Ac-histone in A549 cells with EC50 of 181 uM.
-
DescriptionA novel histone deacetylase (HDAC) inhibitor that induces Ac-histone in A549 cells with EC50 of 181 uM; inhibits the growth of all cell lines and promotes apoptosis in the human leukemia cell lines (NB4, HL-60, THP-1, and K562); induces growth inhibition and apoptosis and downregulates HDAC1-5 and DAPC complex expression levels in cervical cancer cells.
-
In VitroCell Proliferation AssayCell Line:NB4 cells Concentration:10, 20 μM Incubation Time:24, 48 hours Result:Inhibited cell proliferation and growth inhibition of NB4 cells in a dose- and time-dependent manner.Cell Cycle AnalysisCell Line:NB4 cells Concentration:10, 20 μM Incubation Time:24, 48 hours Result:Caused a decrease in the proportion of NB4 cells in the S phase and an increase in the G0/G1 phase.Caused an increase in the G0/G1 phase up to 70% at 24 and 48 h with 10 μM.Cell Cytotoxicity Assay Cell Line:NB4 cells Concentration:10, 20 μM Incubation Time:24, 48 hours Result:Caused cytotoxic effects on NB4 cells in a dose- and time-dependent manner.Apoptosis Analysis Cell Line:NB4 cells Concentration:10, 20 μM Incubation Time:24, 48 hours Result:At a dose of 10 μM induced apoptotic cell death.Western Blot Analysis Cell Line:NB4 cells Concentration:10, 20 μM Incubation Time:24, 48 hours Result:At 10 μM dose inhibited HDAC1 gene expression up to 36% after 48 h of treatment Inhibited HDAC expression up to 74% at 8 h point at 20 μM.
-
In VivoAnimal Model:Female C57BL/6 mice with mouse breast cancer EO771 cells Dosage:20 mg/kg Administration:IP; three times per week for two weeks Result:Notably suppressed the tumour growth and weight.
-
SynonymsBML210 | BML 210
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorHDAC
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number537034-17-6
-
Formula Weight339.4314
-
Molecular FormulaC20H25N3O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 30 mg/mL
-
SMILESO=C(NC1=CC=CC=C1N)CCCCCCC(NC2=CC=CC=C2)=O
-
Chemical NameOctanediamide, N1-(2-aminophenyl)-N8-phenyl-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Savickiene J, et al. Eur J Pharmacol. 2006 Nov 7;549(1-3):9-18.
2. Wong JC, et al. J Am Chem Soc. 2003 May 14;125(19):5586-7.
3. Borutinskaite VV, et al. Mol Biol Rep. 2012 Dec;39(12):10179-86.
molnova catalog
related products
-
BRD9757
BRD9757 is a potent, selective HDAC6 inhibitor with IC50 of 8 nM.
-
FT895
FT895 (FT-895) is a potent and selective inhibitor of HDAC11 with IC50 of 3 nM.
-
Patamostat mesylate
Patamostat mesylate (E-3123) is a potent protease inhibitor with IC50 values of 39 nM for trypsin, 950 nM for plasmin, and 1.9 μM for thrombin.
Cart
sales@molnova.com